Japan · Delayed Price · Currency is JPY Astellas Pharma Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of JPY 4.24 trillion. The enterprise value is 4.58 trillion.
| Market Cap | 4.24T |
| Enterprise Value | 4.58T |
Important Dates
The last earnings date was Wednesday, August 5, 2026.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | Sep 29, 2026 |
Share Statistics
Astellas Pharma has 1.79 billion shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | 1.79B |
| Shares Outstanding | 1.79B |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 51.25% |
| Float | 1.79B |
Valuation Ratios
The trailing PE ratio is 11.64 and the forward PE ratio is 11.94. Astellas Pharma's PEG ratio is 0.69.
| PE Ratio | 11.64 |
| Forward PE | 11.94 |
| PS Ratio | 1.86 |
| PB Ratio | 2.18 |
| P/TBV Ratio | 9.02 |
| P/FCF Ratio | 7.93 |
| P/OCF Ratio | 7.16 |
| PEG Ratio | 0.69 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.86, with an EV/FCF ratio of 8.58.
| EV / Earnings | 12.56 |
| EV / Sales | 2.02 |
| EV / EBITDA | 6.86 |
| EV / EBIT | 9.71 |
| EV / FCF | 8.58 |
Financial Position
The company has a current ratio of 1.20, with a Debt / Equity ratio of 0.30.
| Current Ratio | 1.20 |
| Quick Ratio | 0.88 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | 0.88 |
| Debt / FCF | 1.10 |
| Interest Coverage | 41.87 |
Financial Efficiency
Return on equity (ROE) is 21.30% and return on invested capital (ROIC) is 16.18%.
| Return on Equity (ROE) | 21.30% |
| Return on Assets (ROA) | 8.41% |
| Return on Invested Capital (ROIC) | 16.18% |
| Return on Capital Employed (ROCE) | 19.24% |
| Weighted Average Cost of Capital (WACC) | 4.30% |
| Revenue Per Employee | 161.31M |
| Profits Per Employee | 25.88M |
| Employee Count | 14,099 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.36 |
Taxes
In the past 12 months, Astellas Pharma has paid 107.78 billion in taxes.
| Income Tax | 107.78B |
| Effective Tax Rate | 22.80% |
Stock Price Statistics
The stock price has increased by +46.27% in the last 52 weeks. The beta is 0.08, so Astellas Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | +46.27% |
| 50-Day Moving Average | 2,173.80 |
| 200-Day Moving Average | 2,200.58 |
| Relative Strength Index (RSI) | 67.08 |
| Average Volume (20 Days) | 7,197,425 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of JPY 2.27 trillion and earned 364.94 billion in profits. Earnings per share was 203.04.
| Revenue | 2.27T |
| Gross Profit | 1.84T |
| Operating Income | 472.87B |
| Pretax Income | 472.69B |
| Net Income | 364.94B |
| EBITDA | 669.55B |
| EBIT | 472.87B |
| Earnings Per Share (EPS) | 203.04 |
Balance Sheet
The company has 244.70 billion in cash and 589.87 billion in debt, with a net cash position of -345.17 billion or -192.51 per share.
| Cash & Cash Equivalents | 244.70B |
| Total Debt | 589.87B |
| Net Cash | -345.17B |
| Net Cash Per Share | -192.51 |
| Equity (Book Value) | 1.94T |
| Book Value Per Share | 1,083.48 |
| Working Capital | 250.84B |
Cash Flow
In the last 12 months, operating cash flow was 591.83 billion and capital expenditures -57.53 billion, giving a free cash flow of 534.30 billion.
| Operating Cash Flow | 591.83B |
| Capital Expenditures | -57.53B |
| Depreciation & Amortization | 196.68B |
| Net Borrowing | -319.03B |
| Free Cash Flow | 534.30B |
| FCF Per Share | 297.99 |
Margins
Gross margin is 80.82%, with operating and profit margins of 20.79% and 16.05%.
| Gross Margin | 80.82% |
| Operating Margin | 20.79% |
| Pretax Margin | 20.78% |
| Profit Margin | 16.05% |
| EBITDA Margin | 29.44% |
| EBIT Margin | 20.79% |
| FCF Margin | 23.49% |
Dividends & Yields
This stock pays an annual dividend of 80.00, which amounts to a dividend yield of 3.39%.
| Dividend Per Share | 80.00 |
| Dividend Yield | 3.39% |
| Dividend Growth (YoY) | 3.95% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 38.29% |
| Buyback Yield | -0.01% |
| Shareholder Yield | 3.42% |
| Earnings Yield | 8.61% |
| FCF Yield | 12.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Astellas Pharma is 2,413.08, which is 2.12% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,413.08 |
| Price Target Difference | 2.12% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | -4.50% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.
| Last Split Date | Mar 27, 2014 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Astellas Pharma has an Altman Z-Score of 2.73 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.73 |
| Piotroski F-Score | 7 |